Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytoplasmic dynein 2 light intermediate chain 1 (DYNC2LI1)
- Target
- DYNC2LI1
- Molecular classification
- Microtubule-associated protein, Motor protein accessory subunit, Dynein light intermediate chain, Component of the dynein-2 complex (ciliary/retrograde IFT motor)
01
Overview
Cytoplasmic dynein 2 light intermediate chain 1 (DYNC2LI1) is a protein coded by the DYNC2LI1 gene that acts as a non-catalytic accessory subunit of the dynein-2 motor complex—a multiprotein assemblage responsible for retrograde transport within the cilium via the intraflagellar transport (IFT) system. DYNC2LI1 is required for assembly, stability, and normal function of the dynein-2 motor, and is expressed in all ciliated human tissues with enrichment in brain, kidney, and chondrocytes. Mutations can cause severe congenital ciliopathies, including short-rib thoracic dysplasia, by disrupting ciliary structure, morphology, and signaling pathways such as Hedgehog. DYNC2LI1 does not currently have associated targeted small molecules, but its genetic status is utilized for disease diagnosis and research on ciliary dysfunction
- Other names
- DYNC2LI1D2LICLIC3CGI-60Dynein 2 light intermediate chainDKFZP564A033cytoplasmic dynein 2 light intermediate chain 1
02
Mechanism of action
Not applicable, as there are currently no known drugs that specifically target DYNC2LI1. In principle, gene therapy, molecular chaperones, or modalities that restore dynein-2 complex stability/function could be envisioned for genetic ciliopathies caused by DYNC2LI1 mutation
03
Biological functions
Organelle biogenesisRetrograde transport in cilia (intracellular trafficking)Regulation of ciliary length and morphologyHedgehog signaling pathway regulationAssembly and stability of the dynein-2 complex
04
Disease associations
Ciliopathy (broad spectrum)Skeletal dysplasias (such as short-rib thoracic dysplasia 15 with polydactyly)Sitosterolemia (reported association)
05
Safety considerations
Therapeutic targeting of DYNC2LI1 is constrained by its ubiquitous expression and essential function in all ciliated cells, raising concerns about off-target effects and toxicity if inhibited in healthy tissuesLoss-of-function mutations are linked to severe developmental disorders; functional inhibition would be expected to be deleterious
06
Biomarkers
Mutations in DYNC2LI1 (genetic variants, e.g. missense, nonsense, splice-site defects) are used as diagnostic biomarkers for short-rib thoracic dysplasia 15 with polydactyly and related ciliopathiesAbnormal cilia length/morphology (cellular biomarker for functional studies)
Beyond the preview
Go deeper on Cytoplasmic dynein 2 light intermediate chain 1 (DYNC2LI1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cytoplasmic dynein 2 light intermediate chain 1 (DYNC2LI1).